The mTOR Signalling Pathway in Cancer and the Potential mTOR Inhibitory Activities of Natural Phytochemicals
作者： Heng Kean Tan , Ahmed Ismail Hassan Moad , Mei Lan Tan
DOI: 10.7314/APJCP.2014.15.16.6463
关键词: PI3K/AKT/mTOR pathway 、 RPTOR 、 Hedgehog signaling pathway 、 Kinase 、 Cell growth 、 mTORC1 、 Cell cycle 、 Resveratrol 、 Pharmacology 、 Biology
摘要: The mammalian target of rapamycin (mTOR) kinase plays an important role in regulating cell growth and cycle progression response to cellular signals. It is a key regulator proliferation many upstream activators downstream effectors mTOR are known be deregulated various types cancers. Since the signalling pathway commonly activated human cancers, researchers actively developing inhibitors that components some these drugs already on market. Numerous preclinical investigations have also suggested herbs natural phytochemicals, such as curcumin, resveratrol, timosaponin III, gallic acid, diosgenin, pomegranate, epigallocatechin gallate (EGCC), genistein 3,3'-diindolylmethane inhibit either directly or indirectly. Some compounds clinical trial stage. In this review, potential anti-cancer chemopreventive activities current status trials phytochemicals discussed.
koreascience.or.kr参考文章(160)
Takako Sakamoto, Hyogo Horiguchi, Etsuko Oguma, Fujio Kayama, Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells Journal of Nutritional Biochemistry. ,vol. 21, pp. 856- 864 ,(2010) , 10.1016/J.JNUTBIO.2009.06.010
L ASNAGHI, P BRUNO, M PRIULLA, A NICOLIN, mTOR: a protein kinase switching between life and death. Pharmacological Research. ,vol. 50, pp. 545- 549 ,(2004) , 10.1016/J.PHRS.2004.03.007
Frank W. King, Sylvia Fong, Chandi Griffin, Mark Shoemaker, Rick Staub, Yan-Ling Zhang, Isaac Cohen, Emma Shtivelman, Timosaponin AIII Is Preferentially Cytotoxic to Tumor Cells through Inhibition of mTOR and Induction of ER Stress PLoS ONE. ,vol. 4, pp. e7283- ,(2009) , 10.1371/JOURNAL.PONE.0007283
Dos D. Sarbassov, Siraj M Ali, Do-Hyung Kim, David A Guertin, Robert R Latek, Hediye Erdjument-Bromage, Paul Tempst, David M Sabatini, Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton Current Biology. ,vol. 14, pp. 1296- 1302 ,(2004) , 10.1016/J.CUB.2004.06.054
Gordon M. Cragg, David J. Newman, Kenneth M. Snader, Natural Products in Drug Discovery and Development Journal of Natural Products. ,vol. 60, pp. 52- 60 ,(1997) , 10.1021/NP9604893
Qingsong Liu, Carson Thoreen, Jinhua Wang, David Sabatini, Nathanael S. Gray, mTOR Mediated Anti-Cancer Drug Discovery. Drug Discovery Today: Therapeutic Strategies. ,vol. 6, pp. 47- 55 ,(2009) , 10.1016/J.DDSTR.2009.12.001
J LOPICCOLO, G BLUMENTHAL, W BERNSTEIN, P DENNIS, Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations Drug Resistance Updates. ,vol. 11, pp. 32- 50 ,(2008) , 10.1016/J.DRUP.2007.11.003
Zelton Dave Sharp, Arlan Richardson, Aging and cancer: can mTOR inhibitors kill two birds with one drug? Targeted Oncology. ,vol. 6, pp. 41- 51 ,(2011) , 10.1007/S11523-011-0168-7
Isabelle Sansal, William R. Sellers, The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway Journal of Clinical Oncology. ,vol. 22, pp. 2954- 2963 ,(2004) , 10.1200/JCO.2004.02.141
Yusuke Takahashi, Kenichi Kohashi, Yuichi Yamada, Makoto Endo, Nokitaka Setsu, Takeaki Ishii, Hidetaka Yamamoto, Yukihide Iwamoto, Yoshinao Oda, Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas ☆,☆☆ Human Pathology. ,vol. 45, pp. 984- 993 ,(2014) , 10.1016/J.HUMPATH.2013.12.012